Prim-O-glucosylcimifugin suppresses M2 macrophage polarization via the JAK2-STAT6-PPARγ pathway to alleviate allergic asthma

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

Allergic asthma (AA) is a chronic respiratory disease closely linked to immune-inflammatory responses driven by M2 macrophage polarization. PrimO-glucosylcimifugin (POG), a natural bioactive compound from Saposhnikovia divaricata (SD), alleviates inflammation in acute lung injury mice, but whether it mitigates AA by modulating M2 macrophage polarization remains unclear.

Objective

This study investigated POG’s effects on AA and its mechanisms in regulating M2 macrophage polarization.

Methods

LC-MS profiled the SD/Prunus mume (PM) combination, and network pharmacology predicted its main active components and key anti-AA mechanisms. Ovalbumin (OVA) plus IL-4 established AA models in mice and RAW264.7 cells. Lung protection was assessed by histopathology, lung indices, and type II immune inflammatory cytokine markers. Flow Cytometry, RT-qPCR, immunofluorescence, and Western blot examined key genes/proteins in the JAK2-STAT6-PPARγ axis.

Results

LC-MS-based network pharmacology identified POG as the key SD/PM active ingredient alleviating AA. Pharmacodynamic evaluation showed POG effectively alleviated OVA-induced airway inflammation and pulmonary histopathological damage in AA mice. Mechanistically, POG inhibited M2 macrophage polarization by downregulating key JAK2-STAT6-PPARγ axis factors.

Conclusion

POG ameliorates AA by reducing type II immune factor release through JAK2-STAT6-PPARγ-mediated inhibition of M2 macrophage polarization. This study clarifies POG’s anti-AA mechanism and supports its clinical development.

Article activity feed